| Identification | Back Directory | [Name]
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- | [CAS]
461424-21-5 | [Synonyms]
IDO1/TDO-IN-4
1-(5-Imidazolyl)-9H-pyrido[3,4-b]indole
9H-Pyrido[3,4-b]indole, 1-(1H-imidazol-5-yl)- | [Molecular Formula]
C14H10N4 | [MOL File]
461424-21-5.mol | [Molecular Weight]
234.26 |
| Chemical Properties | Back Directory | [Boiling point ]
627.2±40.0 °C(Predicted) | [density ]
1.410±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
12.79±0.10(Predicted) | [color ]
Yellow to brown |
| Hazard Information | Back Directory | [Uses]
IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and π?π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders[1]. | [in vivo]
IDO1/TDO-IN-4 (compound 28, i.p., 20 mg/kg, at day 1, 2, 3) rescues LPS-induced neuroinflammation and depressive-like behavior in mice[1].
IDO1/TDO-IN-4 (I.p. or i.v., 20 mg/kg) displays high exposure and a high volume of distribution at the steady state in normal mice[1]. | Animal Model: | 2 mg/kg LPS-induced depressive mice[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.), at day 1, 2, 3. | | Result: | Attenuated microglial activation significantly.
Decreased inflammatory factors in the hippocampus, such as TNF-α, IL-1β, and iNOS.
Downregulated LPS-induced overexpression of IDO1.
|
| Animal Model: | Male C57BL/6J mice (pharmacokinetic assay)[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection and intravenous injection | | Result: | Pharmacokinetic profile of IDO1/TDO-IN-4 (compound 28)
| pharmacokinetic property | T1/2 (h) | Tmax (h) | Cmax (ng/mL) | bioavailability F (%) | | i.v./i.p. | 2.31/0.77 | 0.25 | 5543.99/3878 | 52.55 |
|
| [IC 50]
IDO1: 3.53 μM (IC50) | [References]
[1] Yu Zhang, et al. B Discovery of 1-(Hetero)aryl-β-carboline Derivatives as IDO1/TDO Dual Inhibitors with Antidepressant Activity. J Med Chem. 2022 Aug 7. DOI:10.1021/acs.jmedchem.2c00677 |
|
|